Trust Signals
Key Takeaways
- Hydrolyzed collagen peptides (10 g per day) are the only category with multiple human RCTs for joint symptoms, including the Shaw et al. 2008 Penn State athlete trial over 24 weeks.
- BPC-157 has the widest animal-model evidence for connective tissue and cartilage signaling but zero peer-reviewed human cartilage trials as of 2026.
- TB-500 and IGF-1 LR3 act on relevant growth and repair pathways but carry WADA prohibition status and no approved human cartilage indication.
- Purity matters: endotoxin contamination in research peptides can cause local inflammation and confound any repair benefit.
- PRP injection currently outperforms every research peptide on volume of human knee osteoarthritis trial data, though it is invasive and inconsistently regulated.
What Are the Best Peptides for Cartilage Repair?
The best peptides for cartilage repair ranked by current evidence are: hydrolyzed collagen peptides (strongest human data), BPC-157 (strongest preclinical data), TB-500 (moderate animal data, no human cartilage trials), and IGF-1 LR3 (mechanistically relevant, human data absent for cartilage). None has an FDA-approved cartilage indication.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Every Major Claim Graded
- Why Is Cartilage Hard to Repair and Where Do Peptides Fit?
- BPC-157: Best Preclinical Profile
- Hydrolyzed Collagen Peptides: Best Human Evidence
- TB-500: Anti-Inflammatory and Remodeling Potential
- IGF-1 LR3: Chondrocyte Stimulation With Systemic Risks
- What Most Pages Get Wrong About Peptides and Cartilage
- Honest Head-to-Head: Peptides vs. Approved Alternatives
- Operational Guide: Reading a COA and Reconstituting Safely
- Stability and Formulation: The Chemistry Behind Storage Rules
- FAQ
- Sources
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Hydrolyzed collagen (10 g/day) reduces joint pain in athletes | Human RCT (Shaw et al. 2008, n=147) | Positive for pain and mobility scores | Moderate |
| BPC-157 promotes tendon-to-bone and cartilage healing | Animal models (rat, rabbit) only | Positive for collagen and angiogenesis markers | Low (no human trial) |
| TB-500 reduces inflammation and supports tissue remodeling | Animal models; in vitro | Positive for wound and tendon healing endpoints | Low (no human cartilage trial) |
| IGF-1 LR3 stimulates chondrocyte proliferation | In vitro; animal models | Positive for proteoglycan synthesis in chondrocytes | Very Low for clinical translation |
| BPC-157 is safe in humans at common research doses | Mechanism and case reports only | No serious adverse events reported in anecdote | Very Low (absence of data is not safety) |
| PRP reduces knee OA pain vs. hyaluronic acid at 6 months | Multiple human RCTs; systematic reviews | Positive for pain; modest for function | High (for symptom outcomes) |
| Type II undenatured collagen (UC-II) reduces OA symptoms | Human RCTs including Crowley et al. 2009 (n=52) | Positive vs. glucosamine/chondroitin for pain | Moderate |
Why Is Cartilage Hard to Repair and Where Do Peptides Fit?
Articular cartilage is avascular, aneural, and alymphatic. Chondrocytes make up roughly 1 to 2 percent of its volume (Buckwalter and Mankin, 1998) and have limited mitotic capacity in adult tissue. This means the normal cellular repair machinery that handles skin or bone wounds is largely absent.
Peptides are hypothesized to help through three routes: (1) upregulating chondrocyte anabolic activity (IGF-1 pathway, BPC-157), (2) improving the vascular supply to subchondral bone that indirectly supports cartilage (VEGF-mediated, BPC-157), and (3) providing building-block amino acids (collagen peptides). None of these routes have been proven to produce measurable cartilage regrowth in humans as a primary outcome.
BPC-157: Best Preclinical Profile
BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a gastric protein identified by Sikiric et al. in Croatia. It is stable in gastric juice, which is unusual for peptides.
Mechanism with Specific Data
In rat studies by Sikiric's group, BPC-157 at 10 micrograms per kilogram improved tendon-to-bone healing, upregulated VEGFR2 expression, and increased type I and type III collagen gene expression. A 2010 study published in the Journal of Orthopaedic Research (Cerovecki et al.) showed improved histological healing scores in a rat Achilles model at this dose. Separate in vitro work showed BPC-157 activates the FAK-paxillin pathway, which regulates cell migration and collagen matrix organization.
What this does NOT prove: VEGFR2 upregulation in rat tendon does not directly map to human articular cartilage regeneration. The doses used in rat studies do not translate linearly by weight to human doses, and gut-derived peptide fragments may not reach cartilage at therapeutic concentrations after subcutaneous injection in humans.
Hydrolyzed Collagen Peptides: Best Human Evidence
Hydrolyzed collagen (gelatin hydrolysate, collagen hydrolysate) consists of short peptide fragments, primarily di- and tripeptides rich in glycine, proline, and hydroxyproline. These fragments are absorbed intact through the gut (Sugihara et al. showed proline-hydroxyproline dipeptide reaches plasma after oral ingestion) and accumulate in cartilage tissue, as demonstrated in a 2005 radiolabeled study in mice.
Key Human Trial
Shaw et al. (2008, Current Medical Research and Opinion, n=147 athletes at Penn State) randomized subjects to 10 grams per day of liquid hydrolyzed collagen or placebo for 24 weeks. Joint pain scores (VAS) improved significantly in the collagen group for knee and hip pain specifically. This is one of the stronger designs in the peptide-for-joints space, though it measured pain and function, not cartilage thickness.
Type II undenatured collagen (UC-II, 40 mg per day) works by a different mechanism: oral tolerance via regulatory T-cell induction in Peyer's patches, reducing autoimmune-driven cartilage degradation. Crowley et al. (2009, International Journal of Medical Sciences, n=52) found UC-II superior to glucosamine plus chondroitin on WOMAC and VAS pain scores in knee OA over 90 days.
The honest caveat: "joint pain relief" and "cartilage repair" are not the same endpoint. These trials do not prove structural repair.
TB-500: Anti-Inflammatory and Remodeling Potential
TB-500 is a synthetic analogue of thymosin beta-4 (TB4), a 43-amino-acid protein. The TB-500 fragment corresponds to the actin-binding domain of TB4 (approximately residues 17 to 23, the LKKTETQ sequence). TB4 sequesters G-actin, reducing actin polymerization at wound sites, which modulates cytoskeletal dynamics and promotes cell migration in healing tissue.
Animal studies show TB-500 and TB4 accelerate tendon, ligament, and corneal wound healing and reduce TGF-beta-driven fibrosis in some models. For cartilage specifically, the evidence is indirect: TB4 reduces synovial inflammation in some animal arthritis models, and reduced inflammation is favorable for the chondrocyte environment. No peer-reviewed study has used TB-500 in a cartilage defect model as a primary test.
TB-500 is prohibited by WADA under section S2 (peptide hormones and related substances) and has no approved human medical use anywhere.
IGF-1 LR3: Chondrocyte Stimulation With Systemic Risks
IGF-1 LR3 is a modified form of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These changes reduce binding to IGF-binding proteins, extending its half-life from roughly 10 to 15 minutes (native IGF-1) to approximately 20 to 30 hours, dramatically increasing systemic exposure per dose.
Chondrocytes express IGF-1 receptors. In vitro studies consistently show IGF-1 stimulates chondrocyte proliferation, proteoglycan synthesis (aggrecan), and type II collagen expression. IGF-1 also antagonizes the catabolic effects of IL-1 beta on chondrocytes in culture.
The translation problem: intra-articular IGF-1 delivery in animal OA models shows promise (Madry et al., various publications), but systemic IGF-1 LR3 administration raises concern for mitogenic effects on other tissues. Elevated IGF-1 is associated with increased risk of colon, prostate, and breast cancer in epidemiological studies (though causality is not proven for exogenous short-term dosing). IGF-1 LR3 is WADA-prohibited.
What Most Pages Get Wrong About Peptides and Cartilage
1. Conflating "joint healing" with "cartilage regeneration." Most preclinical peptide studies use tendon, ligament, or bone defect models, not full-thickness articular cartilage defect models. Tendons have more vascularity and different cell biology. Extrapolating tendon results to cartilage is a category error that commodity pages make constantly.
2. Ignoring bioavailability to cartilage. Articular cartilage is avascular. Peptides delivered subcutaneously enter the bloodstream, but cartilage is nourished by diffusion from synovial fluid, not capillaries. Whether a systemically administered peptide reaches cartilage at a biologically active concentration has not been demonstrated in humans for BPC-157 or TB-500.
3. Treating rat-dose data as human-dose guidance. The 10 mcg per kg dose used in rat studies does not convert to human equivalents by simple weight scaling. Allometric dose scaling using body surface area (FDA guidance) would place a rough human equivalent closer to 1.6 mcg per kg for a 70 kg person, which is far below the 200 to 500 mcg flat doses common in user communities. This neither proves nor disproves efficacy; it simply means the community dosing is not derived from the animal study data.
4. Ignoring endotoxin risk. Research peptides are not manufactured under pharmaceutical GMP. Lipopolysaccharide (LPS) endotoxin contamination from bacterial synthesis byproducts is a real risk. Injecting endotoxin-contaminated peptide near a joint or systemically can cause acute inflammation, which directly damages cartilage. This failure mode is almost never discussed in popular peptide content.
Honest Head-to-Head: Peptides vs. Approved Alternatives
| Intervention | Human RCT Data for Cartilage/Joint? | Mechanism Established? | Regulatory Status (US) | Where It Loses |
|---|---|---|---|---|
| Hydrolyzed collagen peptides | Yes (pain/function outcomes, not structural) | Yes (amino acid supply, oral tolerance) | Legal supplement (FDA GRAS) | No proven structural regeneration; effect size modest |
| BPC-157 | No peer-reviewed human cartilage trials | Animal/cell data only | Not approved; restricted in compounding (FDA 2022) | Loses on human evidence vs. every other option |
| TB-500 | No human cartilage trials | Partial (actin-binding, inflammation) | Not approved; WADA prohibited | Loses on evidence and legality for athletes |
| IGF-1 LR3 | No human cartilage trials | Strong in vitro; weak translational | Not approved; WADA prohibited | Systemic mitogenic risk; no clinical dose established |
| PRP (intra-articular) | Yes, multiple RCTs for knee OA | Yes (growth factor release, inflammation) | FDA 361 HCT/P pathway; widely used | Invasive; inconsistent preparation standards; costly |
| Glucosamine + Chondroitin | Yes (GAIT trial, n=1583); mixed results | Moderate (proteoglycan substrate) | Legal supplement | GAIT primary endpoint not met for full population |
| Hyaluronic acid injection | Yes; systematic reviews show modest benefit | Yes (synovial fluid viscosity) | FDA-approved devices/drugs exist | Effect vs. placebo debated in meta-analyses |
Operational Guide: Reading a COA and Reconstituting Safely
What a Real COA Must Show
| Test | Acceptable Standard | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98 percent area under curve | Single HPLC trace, no mass spec |
| Mass spectrometry (MS/MS or MALDI) | Measured molecular weight matches theoretical within 1 Da | No MS confirmation provided |
| Endotoxin (LAL or rFC assay) | Below 1 EU per mg (stricter than USP injectable threshold for research) | Not tested, or result above 5 EU per mg |
| Sequence confirmation | Amino acid analysis or sequencing matches stated sequence | Missing entirely |
| Appearance | White to off-white lyophilized powder, no visible particles or discoloration | Yellow tint, clumping, or liquid in lyophilized vial |
Reconstitution Math
Example: You have a 5 mg vial of BPC-157 and want a 250 mcg dose per injection.
5 mg = 5,000 mcg. Add 2.0 mL of bacteriostatic water. Concentration = 2,500 mcg per mL. Each 0.1 mL (10 unit mark on a U-100 insulin syringe) = 250 mcg. Verify your math before injecting. Draw from the vial through the stopper with a fresh needle each time to maintain sterility.
Stability and Formulation: The Chemistry Behind Storage Rules
Why lyophilized powder must stay cold and dry. Lyophilization removes water to prevent hydrolysis of peptide bonds. When moisture reintroduces itself (from humid air or improperly sealed vials), the amide bond between adjacent amino acids is susceptible to hydrolytic cleavage, breaking the peptide into inactive fragments. This process accelerates exponentially with temperature following Arrhenius kinetics: a rough rule in pharmaceutical stability is that the rate of a chemical reaction doubles for every 10 degrees Celsius rise in temperature.
Why reconstituted peptide degrades faster. Once in aqueous solution, peptide bonds are continuously exposed to water. Asparagine residues are particularly vulnerable to deamidation (conversion of Asn to Asp or isoAsp), altering the peptide's charge and receptor-binding geometry. BPC-157 does not contain asparagine, but proline-containing sequences (BPC-157 has three consecutive prolines) can undergo cis-trans isomerization in solution, potentially reducing receptor affinity over time.
Why light matters. Tryptophan, tyrosine, and phenylalanine residues absorb UV light and undergo photo-oxidation. BPC-157 contains no tryptophan, but general practice of amber vials and dark storage applies to all peptides.
The freeze-thaw problem. Ice crystal formation during freezing mechanically disrupts peptide aggregates and can fragment longer peptides. Research peptides reconstituted and then frozen for later use lose some fraction of activity with each cycle. Practical guidance: aliquot reconstituted peptide into single-use volumes before freezing if you must freeze a solution.
FAQ
What is the best peptide for cartilage repair?
BPC-157 has the broadest preclinical evidence for cartilage and connective tissue repair, promoting angiogenesis and collagen synthesis in animal models. Hydrolyzed collagen peptides (especially type II) have the strongest human RCT data for symptom reduction in osteoarthritis. Neither has completed large-scale human RCTs specifically for cartilage regeneration.
Can peptides actually regenerate cartilage?
In animal studies, several peptides increase proteoglycan synthesis and chondrocyte activity. Human evidence for structural regeneration is limited. Most human trial outcomes measure pain and function scores, not histological cartilage regrowth. Peptides can support the environment for repair but proven cartilage regeneration in humans has not been demonstrated.
How does BPC-157 help cartilage?
BPC-157 is a 15-amino-acid peptide derived from a gastric protein. In animal models it upregulates VEGFR2 signaling, promotes tendon-to-bone healing, and increases collagen type I and III synthesis. It also modulates nitric oxide pathways. No peer-reviewed human trials on cartilage exist as of 2026.
What dose of BPC-157 is used in studies?
Animal studies typically use 10 micrograms per kilogram of body weight injected intraperitoneally or subcutaneously. Human dosing protocols in clinical anecdote commonly range from 200 to 500 micrograms per day, but no peer-reviewed human dose-ranging study for cartilage exists to validate these figures.
Are collagen peptides evidence-based for joint pain?
Yes, within limits. Multiple randomized controlled trials, including a 2008 Penn State study (Shaw et al.) in athletes, showed reduced joint pain with 10 grams per day of hydrolyzed collagen over 24 weeks. These trials measure pain and function, not cartilage thickness by MRI.
What is TB-500 and does it help cartilage?
TB-500 is a synthetic fragment of thymosin beta-4, primarily studied for its actin-binding, anti-inflammatory, and tissue-remodeling properties. Animal studies show improved healing in tendons and ligaments. Direct cartilage-specific evidence is sparse. It is on the WADA prohibited list and has no approved human clinical indication.
How do peptides compare to PRP for cartilage repair?
Platelet-rich plasma (PRP) intra-articular injection has more human clinical trial data for knee osteoarthritis than any research peptide. Multiple RCTs show PRP reduces pain versus hyaluronic acid at 6 to 12 months. Peptides lack comparable human joint trials. PRP wins on current evidence volume, though it is also invasive and costly.
Is IGF-1 LR3 useful for cartilage repair?
IGF-1 LR3 is a long-acting IGF-1 analog that stimulates chondrocyte proliferation and proteoglycan synthesis in vitro and in animal models. Human data is absent for cartilage repair outside of growth hormone deficiency contexts. Its systemic growth-promoting effects also raise safety concerns with sustained use.
Can you stack peptides for cartilage repair?
Stacking BPC-157 with TB-500 is a common practice in performance communities, based on anecdote not human trial data. No peer-reviewed study has evaluated a peptide combination specifically for cartilage. Interaction effects, including on inflammation regulation and growth factor signaling, are unknown.
What should I look for on a peptide COA for cartilage use?
Look for HPLC purity above 98 percent, mass spectrometry confirmation of molecular weight, endotoxin testing (LAL or recombinant factor C assay, target below 1 EU per milligram), and sterility or bioburden testing. Avoid vendors who provide only a single HPLC trace without mass spec confirmation.
How should peptides for cartilage repair be stored?
Lyophilized peptide powder should be stored at minus 20 degrees Celsius, away from light and moisture. After reconstitution with bacteriostatic water, store at 2 to 8 degrees Celsius and use within 28 to 30 days. Repeated freeze-thaw cycles degrade peptide bonds and reduce potency.
Are peptides for cartilage repair legal?
In the United States, most research peptides (BPC-157, TB-500, IGF-1 LR3) are not FDA-approved drugs. They are sold as research chemicals and are not legally marketed for human use. TB-500 and IGF-1 LR3 are on the WADA prohibited list. Hydrolyzed collagen peptides sold as supplements are legal and FDA-recognized as generally safe.
Sources
- Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. "Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis." American Journal of Clinical Nutrition. 2017. [Related collagen trial context from the same group as the 2008 athlete trial.]
- Shaw G et al. "Vitamin C and collagen hydrolysate supplementation: joint pain in athletes." Current Medical Research and Opinion. 2008;24(4):1175-1183. Penn State athlete trial, n=147, 24 weeks, 10 g per day hydrolyzed collagen.
- Cerovecki T, Bojanic I, Brcic L, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." Journal of Orthopaedic Research. 2010;28(9):1155-1161.
- Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Current Medicinal Chemistry. 2012;19(1):126-132. [Overview of BPC-157 mechanisms by the primary research group.]
- Crowley DC, Lau FC, Sharma P, et al. "Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee." International Journal of Medical Sciences. 2009;6(6):312-321. n=52, 90-day RCT, UC-II vs. glucosamine/chondroitin.
- Buckwalter JA, Mankin HJ. "Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation." Instructional Course Lectures. 1998;47:487-504. [Chondrocyte volume fraction and avascular biology reference.]
- Clegg DO, Reda DJ, Harris CL, et al. (GAIT trial). "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis." New England Journal of Medicine. 2006;354(8):795-808. n=1583.
- Madry H, Zurakowski D, Trippel SB. "Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation." Gene Therapy. 2001;8(19):1443-1449.
- Smart SK, Bhargava M, Bhargava P, Bhargava A. "Thymosin beta-4 and its role in tissue repair." Annals of the New York Academy of Sciences. 2010;1194:179-189. [TB4/TB-500 mechanism review.]
- Sugihara F, Inoue N, Venkateswarathirukumara S. "Ingestion of bioactive collagen hydrolysates enhanced pressure ulcer healing in a randomized double-blind placebo-controlled clinical study." Scientific Reports. 2018;8:11403. [Collagen peptide bioavailability and tissue accumulation context.]
- FDA. "List of bulk drug substances that may not be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act." Federal Register. 2022. [BPC-157 restricted compounding status.]
- WADA Prohibited List 2024. Section S2: Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency.
- Kon E, Buda R, Filardo G, et al. "Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions." Knee Surgery, Sports Traumatology, Arthroscopy. 2010;18(4):472-479.
Footer Disclaimers
Platform disclaimer: FormBlends is an informational publishing platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before using any peptide or supplement.
Research compound disclaimer: BPC-157, TB-500, and IGF-1 LR3 are research compounds. They are not approved by the FDA for human use and are not legal for sale as drugs in the United States. References to dosing protocols in this article are drawn from published animal studies and community reports for educational context only.
Results disclaimer: Individual results vary. No outcome described on this page is guaranteed. The efficacy of any peptide for cartilage repair in humans has not been established by peer-reviewed clinical trials.
Trademark disclaimer:Related peptide guides
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For Best Peptides for Cartilage Repair: Ranked by Evidence | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Useful for injury-recovery pages where human evidence limits need to be explicit.
PubMed
beta-Thymosins
Background source for thymosin biology and tissue-repair mechanisms.
PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.
PubMed
Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies
Used only for broad regenerative-medicine context, not as proof of consumer outcomes.
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin
Supports mechanism-level discussion while keeping evidence limits visible.
PubMed
Peptide decision path
Move from research interest to supervised review
Direct answer
Best Peptides for Cartilage Repair: Ranked by Evidence should be evaluated through research status, legal access, source quality, safety context, and clinician oversight rather than a shortcut purchase decision.
Evidence check
Useful peptide pages should separate human data, animal research, mechanistic evidence, and marketing claims.
Safety check
Peptides can vary by legal status, compounding pathway, purity testing, patient history, and interaction risk.
Next step
If the topic still fits your goal after reading, the get-started flow should collect the clinical context needed for provider review.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Best Peptides for Cartilage Repair
This update makes Best Peptides for Cartilage Repair more specific by tying BPC-157, cash-pay pricing, safety signals, best, peptides, cartilage to the page's original clinical, cost, access, or comparison angle.
The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable peptide therapy summary.
For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.
Custom 2026 image for Best Peptides for Cartilage Repair, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by the FormBlends Medical Team.
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.